ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO559

Baseline Characteristics of Renal Biopsy Cohort of Patients With CKDu in Nicaragua

Session Information

  • Pathology and Lab Medicine
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pathology and Lab Medicine

  • 1700 Pathology and Lab Medicine

Authors

  • Urey, Cristian J., MINSA, Chinandega, Nicaragua
  • Garcia Salazar, Nelson Benito, MINSA, Chinandega, Nicaragua
  • Workeneh, Biruh, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
  • Mikhailov, Alexei V., Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
  • Carstens, Michael H., Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
  • Mandayam, Sreedhar A., The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Background

CKDu represents a devastating form of kidney disease in young adults in Central America with no traditional risk factors for CKD. Renal biopsy studies of patients with CKDu have been rare. We report the baseline characteristics of a cohort of patients with CKDu that underwent renal biopsy in Leon and Chinandega, Nicaragua

Methods

Study was approved by local IRB and MINSA, Nicaragua. After signing informed consent, patients with CKDu were identified by treating nephrologists and admitted to Hospital Escuela Oscar Danilo Rosales Argüello for renal biopsy. Ultrasound guided percutaneous renal biopsy was performed under conscious sedation and local anesthesia. 2-3 cores were sampled in each patient and verified for adequacy

Results

32 patients were screened for kidney biopsy for CKDu with baseline CBC, BP and Coagulation panel 24 hours pre biopsy. 3 patients were not biopsied for safety concerns (small kidney size, uncontrolled HTN). 14 were female, Mean age of patients was 34 years. Mean serum creatinine at biopsy was 1.4mg/dl. All patients had post biopsy ultrasound to r/o bleeding complications and labs at 24 hours to confirm absence of significant bleeding or other complications

Conclusion

Ultrasound guided percutaneous renal biopsy can be safely conducted in resource poor settings to help diagnose and manage patients with CKDu.